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step process starting from dysplastic lesions to early carcinomas
(eHCC) that ultimately progress to HCC (pHCC). However, the
sequential molecular alterations driving malignant transforma-
tion of the pre-neoplastic lesions are not clearly deﬁned. This lack
of information represents a major challenge in the clinical man-
agement of patients at risk.
Methods:We applied next-generation transcriptome sequencing
to tumor-free surrounding liver (n = 7), low- (n = 4) and high-
grade (n = 9) dysplastic lesions, eHCC (n = 5) andpHCC (n = 3) from
8 HCC patients with hepatitis B infection. Integrative analyses of
genetic and transcriptomic changes were performed to character-
ize the genomic alterations during hepatocarcinogenesis.
Results:We report that changes in transcriptomes of early
lesions including eHCC were modest and surprisingly homoge-
nous. Extensive genetic alterations and subsequent activation of
prognostic adverse signaling pathways occurred only late during
hepatocarcinogenesis and were centered on TGFb, WNT, NOTCH,
and EMT-related genes highlighting the molecular diversity of
pHCC. We further identify IGFALS as a key genetic determinant
preferentially down-regulated in pHCC.
Conclusions: Our results deﬁne new hallmarks in molecular
stratiﬁcation and therapy options for patients at risk for HCC,
and merit larger prospective investigations to develop a modiﬁed
clinical-decision making algorithm based on the individualized
next-generation sequencing analyses.
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Human hepatocarcinogenesis is a multi-step process starting
from chronically altered hepatic microenvironment with dysplas-
tic lesions to early carcinoma (eHCC) that ultimately progresses
to HCC (pHCC) [1]. Four sequential morphological lesions charac-
terized by distinctive clinicopathological features, i.e., dysplastic
lesions, early well-differentiated HCC (eHCC) and progressed
HCC (pHCC), are recognized during human hepatocarcinogenesis
[2]. Dysplastic nodules (DN) are deﬁned as hepatocyte-like
lesions without unambiguous criteria of malignancy. Depending
on the degree of dysplasia, they are divided into low (LGDN)
and high grade (HGDN). However, diagnosis of pre-malignant
lesions and discrimination from eHCC is often difﬁcult, and,
although dysplastic nodules are considered monoclonal in origin,
a clear probability of malignant transformation could not be
attributed to a speciﬁc pre-neoplastic lesion [3].
According to current clinical guidelines, advanced HCCs are
diagnosed with the use of a single dynamic imaging technique
with biopsies being optional and most often reserved for ambig-
uous cases [4]. Further, in clinical routine small lesions such as
DN and potentially some of the more advanced HCCs are usually
followed by ultrasound until further progression. These ﬁndings
might account for recent observations that undiagnosed HCCs
are found by histopathological examinations of explanted livers
following liver transplantation. Therefore, preexisting lesions
are likely contributing to the high rate of recurrent disease after
putative curative treatment and limit the overall survival [4,5].
Therefore, deﬁnition of the sequential molecular events leading
to HCC is urgently needed and represents a major challenge in
the clinical management of patients at risk.
The main objective of this study was to apply next-generation
mRNA sequencing (RNA-Seq) technology to comprehensively
deﬁne changes in the transcriptome of liver cancer during the
sequential evolution of pre-neoplastic lesions into HCC. We show
here that changes in molecular proﬁles of dysplastic lesions and
eHCC were small and quite uniform in contrast to a striking
increase in both the extent and heterogeneity in pHCC at both
mRNA and DNA levels. A massive deregulation of key oncogenic
molecules, such as TGFb1, MYC, PI3K/AKT, pro-metastatic/EMT14 vol. 60 j 346–353
Table 1. Clinicopathological information and HCC marker expression.
Clinicopathological information Marker expression
Patient No. Sex Age
(yr) 
Intrahepatic 
metastasis
Vascular 
invasion 
Lesion Size (cm) GPC3 HSP70 GS K19 AFP 
1 M 68 No No LGDN 0.8 x 0.8 Neg Neg Neg Neg Neg 
HGDN 1.5 x 1.4 Neg Neg Neg Neg Neg 
2 M 54 No No HGDN 0.8 x 0.8 Neg Neg Neg Neg Neg
HGDN 0.8 x 0.7 Neg Neg Neg Neg Neg
eHCC 1.2 x 1.0 Neg Neg Pos Neg Neg
pHCC 3.0 x 2.0 Neg Posa Neg Neg Neg
3 F 42 No No HGDN 1.0 x 0.9 Neg Weaka Neg Neg Neg
4 M 64 No No HGDN 1.5 x 1.3 Neg Neg Weaka Neg Neg
5 M 61 No No LGDN 1 x 0.8 Neg Neg Neg Neg Neg
LGDN 0.8 x 0.8 Neg Neg Neg Neg Neg
LGDN 1.2 x 1.1 Neg Neg Neg Neg Neg
HGDN 1.0 x 1.0 Neg Neg Neg Neg Neg
HGDN 1.3 x 0.9 Neg Neg Pos Neg Neg
HGDN 1.0 x 1.1 Neg Weaka Pos Neg Neg
eHCC 1.6 x 1.4 Weaka Posa Pos Neg Neg
pHCC 3.8 x 3.2 Weaka Posa Pos Neg Neg
6 M 61 No No eHCC 2 x 1.9 Neg Weaka Neg Neg Neg
7 M 50 No No eHCC 1 x 1.3 Neg Weak Neg Neg Neg
8 F 60 No No HGDN 1.0 x 1.0 Neg Neg Neg Neg Neg
eHCC 1.1 x 1.0 Pos Posa Pos Neg Posa
pHCC 1.2 x 1.0 Pos Posa Pos Neg Neg 
aFocal positivity.
Neg, negative staining; Weak, weak staining; Pos, positive staining.
JOURNAL OF HEPATOLOGYSNAIL and Twist, NOTCH, WNT/b-Catenin and MET, was observed
in pHCC, suggesting that activation of prognostically adverse sig-
naling pathways is a late event during hepatocarcinogenesis.
Additionally, we identiﬁed a down-regulation of IGFALS as a com-
mon feature in a large proportion of HCC patients, indicating that
IGFALS might be a useful diagnostic and/or therapeutic target.Materials and methods
Samples
A total of 28 samples were collected, including 7 surrounding liver tissues, 4 low-
grade dysplastic nodules (LGDN), 9 high-grade dysplastic nodules (HGDN), 5 early
HCC (eHCC), and 3 progressed HCC (pHCC). The nodules were resected from
explanted cirrhotic livers from 8 patients with chronic hepatitis B infection. All
lesions were classiﬁed according to the criteria of ‘‘International Consensus Group
for Hepatocellular Neoplasia’’ by two independent expert pathologists [2]. All
procedures were approved by the local authorities and prior patient consent
was obtained. Demographic and clinicopathological data of the patients can be
found in Table 1.
Next generation transcriptome sequencing
RNA isolation was performed using Qiagen RNEasy mini Kit (Qiagen GMBH, Hil-
den, Germany) according to the instructions provided by the manufacturer and
quality assessment was performed using a Nanodrop ND-1000 Spectrophotome-
ter (NanoDrop Technologies, Wilmington, DE) and Agilent 2100 Bioanalyzer (Agi-
lent, Palo Alto, CA). Each sample was sequenced in one sequencing lane with
107 bp paired-end sequencing in an Illumina GAII (Solexa) and 100 bp in an Illu-
mina HiSeq2000 sequencer (SRA accession number: SRP030040). Illumina stan-
dard pipeline and software-CASAVA, GAII and HiSeq2000 were employed for
processing of raw images, base calling and generating FASTQ sequence reads from
paired-end RNA-sequencing data. The reads sequences were 107 bp (GAII) and
100 bp (HiSeq2000) and aligned to the GRCH37.p5 Primary Assembly and hg19Journal of Hepatology 201human reference genome in CLC Genomics Workbench-5.0.1 (CLC bio, Cam-
bridge, MA) and bowtie-0.12.7, respectively [6]. Before aligning reads, we ﬁltered
low quality reads, reads containing adapter sequences, and duplicate mapping
reads using Samtools [7], Picard (http://picard.sourceforge.net), and FASTX-Tool-
kit (FASTQ/A short-reads pre-processing tools, hannonlab.cshl.edu/fastx_toolkit).
The abundance of the expression of a transcript was measured as the score of
RPKM (Reads Per Kilobase of exon model per Million mapped reads) [8] in CLC
Genomics Workbench. We applied Quartile Normalization to all 28 samples to
reduce variations across samples. Among a total of 36,036 transcripts, transcripts
(12,125) that had differently expressed with normal liver were used for further
analysis by applying equivalence test. Analysis of differential expression was per-
formed by an in house Bootstrap 1-way ANOVA script and Bootstrap t test. For the
longitudinal analysis of PT5, we identiﬁed differently expression transcripts with
DEGseq [9] and Chi-square test with Bonferroni adjusted p value. Cluster analysis
was performed using Cluster and TreeView programs from the Michael Eisen Lab-
oratory, Lawrence Berkeley National Laboratory and University of California,
Berkeley; (http://rana.lbl.gov/eisen/). Functional classiﬁcation and network analy-
sis were performed using Ingenuity Pathway Analysis (Ingenuity Systems Inc.) and
the GeneGo pathways analysis (Pathway Analysis MetaCore – GeneGo Inc., St.
Joseph, MI) tools. Venn-Diagrams were generated using the VENNY software by
JC. Oliveros (bioinfogp.cnb.csic.es/tools/venny/index.html). We identiﬁed known
SNVs, novel SNVs, somatic SNVs, In/Del from Samtools [7], VarScan [10] and CLC
Genomic Workbench. We also ﬁltered and annotated genetic variants by using
ANNOVAR software [11]. To minimize errors, we applied reads whose base quality
score is greater than 20. We also ﬁltered our SNVs against dbSNP135 and the 1000
genome project released April 2012. To establish a baseline reference, correspond-
ing surrounding liver was used since no blood/skin tissue was available.Results
RNA sequencing and baseline characteristics of the lesions
We used paired-end second-generation mRNA sequencing (RNA-
Seq) to explore in detail the relationship and sequential evolution
of pre-neoplastic lesions into HCC in 8 individuals with chronic
hepatitis B (HBV) infection (Table 1; Supplementary Fig. 1).4 vol. 60 j 346–353 347
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MYC13 1.75 <0.001
PI3K/Akt21 1.47 0.04
Metastasis/EMT14 1.60 0.03
Notch19 1.50 0.03
S1 (Wnt activation)14 2.85 <0.001
MET20 2.87 <0.001
Hepatoblastoma subtype18 2.64 <0.001
Proliferation15 2.61 <0.001
Fig. 1. Molecular heterogeneity drives late stage activation of adverse signaling pathways. (A) Whole transcriptome correlations among the lesions for each
morphological stage. p Values were calculated using a 1-way ANOVA. A signiﬁcantly reduced correlation was demonstrated for pHCCs (p value <0.001). (B) Number of
signiﬁcant genes in the whole group comparison and in patient 5. (C) Activated gene sets in pHCC as determined by Gene Set Enrichment analyses (GSEA). Normalized
Enrichment score (NES) reﬂects degree of over-representation for each group at the peak of the entire set. Statistical signiﬁcance calculated by nominal p value of the NES by
using an empirical phenotype-based permutation test. (D) Chromosomal distribution of SNVs overlapping and non-overlapping with the identiﬁed PT5 gene expression
signature. Shown are the total numbers of affected genes for each chromosome.
Research ArticleRNA-Seq generated from 7,280,568 to 371,183,770 reads that
were aligned to the human reference GRCh37.p5/hg19, repre-
senting an average genome-coverage of 105x (Supplementary
Table 1).
To establish baseline morphological characteristics of every
lesion, we assessed expression of well-known markers (AFP,
GPC3, GS, and HSP70) associated with liver cancer by immunohis-
tochemistry (Table 1; Supplementary Fig. 2). The majority of the
pre-neoplastic samples were negative for all markers, whereas
eHCC and pHCC showed heterogeneous expression patterns.
None of the single markers successfully distinguished the pre-
malignant from the more advanced lesions, supporting current
clinical management guidelines, highlighting the need for predic-
tive biomarkers in liver cancer [4].Group comparison of the different stages in hepatocarcinogenesis
We next computed the whole transcriptome correlations for each
lesion at the corresponding stage based on RPKM quantile nor-
malized expression values. As anticipated, the gene expression
proﬁles of surrounding livers (SL) were very homogeneous (Pear-
son correlation r = 0.89) (Fig. 1A). Unexpectedly, high homogene-
ity was also observed for LGDNs (r = 0.91), HGDNs (r = 0.89) and348 Journal of Hepatology 201eHCCs (r = 0.88). However, it dramatically decreased upon pro-
gression to pHCC (r = 0.78; p <0.001) (Fig. 1A), reﬂecting a well-
recognized phenotypic heterogeneity of advanced liver cancer.
The gene expression signatures were then deﬁned for each
type of lesions using a 1-way ANOVA and Bootstrapping t test
approach. A total of 234 and 123 genes were speciﬁcally associ-
ated with progression from LGDN to HGDN and to eHCC, respec-
tively, demonstrating limited transcriptomic changes and
homogeneous nature of pre-neoplastic stages in hepatocarcino-
genesis (Fig. 1B; Supplementary Table 2). Major functional net-
works in HGDNs were involved in oxidative stress, glutathione
metabolism, and apoptosis with addition of cell cycle, immune
response and stellate cell activation in eHCC (Supplementary
Fig. 3A). Progression to pHCC was accompanied by a striking
increase in the number of signiﬁcant genes (1486 genes)
(Fig. 1B) associated with malignancy and metastatic spread,
including TGFb, VEGF, and NOTCH/y-secretase target genes
involved in cell adhesion, cytoskeleton remodeling and epithe-
lial-to-mesenchymal transition (EMT) (Supplementary Fig. 3A
and B) [12].
Among the most signiﬁcant molecular changes driving pro-
gression to pHCC was a clear enrichment of several published
gene sets associated with poor outcome in HCC and dependent
on activation of key oncogenic drivers including TGFb1, MYC,4 vol. 60 j 346–353
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PI3K/AKT, pro-metastatic/EMT SNAIL and Twist, NOTCH,
WNT/b-Catenin, and MET (Fig. 1C–F; Supplementary Figs. 4 and
5) [13–21].
To directly test the clinical signiﬁcance of pHCC gene signature,
we next applied it to a cohort of 53 human HCCs [22]. Hierarchical
clustering analysis demonstrated a signiﬁcant overlap with prog-
nostic HCC subtypes (Supplementary Fig. 6A) [18]. Subsequent
analyses of patient outcomes revealed a strong association with
a shorter survival (p = 0.009) and increased tumor recurrence
(p = 0.003) (Supplementary Fig. 6B–C). Further, a meta-analysis
using publically available transcriptome data from more than 40
cancer entities conﬁrmed a prognostic implication of the pHCC
signature for cancers other than HCC (Supplementary Fig. 6D).
Horizontal analyses of malignant transformation in PT5
A clear advantage of this study was the acquisition of samples at
the sequential stages of hepatocarcinogenesis. In particular, one
patient (referred to as PT5) presented a complete sequence of
lesions including SL, LGDN, HGDN, eHCC, and pHCC (Table 1; Sup-
plementary Fig. 2). To gain a more in-depth understanding of the
consecutive molecular stages, we performed an integrative anal-
ysis of whole transcriptomic changes and somatic mutations (i.e.,
single nucleotide variances (SNVs)) located within the exonic
regions of signiﬁcant transcripts. Supporting the group compari-
son data, the number of signiﬁcant genes was relatively limited in
HGDN (600 genes) and eHCC (362 genes) but greatly increased
upon progression to pHCC (2166 genes) (Fig. 1B; SupplementaryA
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Journal of Hepatology 201Table 3). The transcriptome analysis of LGDN to HGDN also
revealed deregulation of signaling pathways involved in metabo-
lism followed by activation of immune response in eHCC (Supple-
mentary Fig. 7A). Consistently, the majority of networks activated
during the conversion to pHCC conferred malignant and invasive
properties, i.e., cell adhesion and EMT (Supplementary Fig. 7B–E).
Genetic landscape of mutations during liver cancer development
Next, we deﬁned the landscape of somatic mutations in the
lesions from PT5. First, the total number of exonic SNVs were
assessed in the different lesions and integrated with our RNA
seq data to identify SNVs with putative effect on gene expression
(Supplementary Fig. 1). While the overlap of SNVs and signiﬁcant
genes in the early lesions was minimal (15 HGDN and 1 eHCC),
among the 2166 signiﬁcant genes in pHCC, 735 genes (29.5%)
showed alterations both on mRNA and DNA levels (Supplemen-
tary Tables 3–5). The latter included key cancer-associated genes
NOTCH2, VCAM1, JAK1, ITGA6, ITGB1, IGF2, IGFBP5, XRCC5, DKK3,
and MMP14. Interestingly, while most of the overlapping and
non-overlapping genes were equally distributed across chromo-
somes, an increased number of genes with overlapping SNVs
were located on chromosomes 4, 9, 11, 14, and 20 (Fig. 1D). Con-
versely, genes located on chromosome 1, 17, 19, and X seem to be
less affected by genetic alterations suggesting another mode of
activation.
Our analysis also identiﬁed previously unrecognized SNVs.
The number of unique and novel exonic SNVs was low in LGDND
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Research Article(9), HGDL (15), and eHCC (2) but drastically increased during
conversion to pHCC (460 SNVs) (Fig. 2A). Despite the extensive
differences in number, the most common proportional nucleotide
exchange in the different lesions were AT>>all changes. In con-
trast to a recent study we also did not observe the over-represen-
tation of GC>>TA changes [23]. However, supporting a late stage
acquisition of the genetic alterations, both GC>>TA and GC>>CG
changes were predominantly seen in pHCC (Fig. 2B). SNVs in
pHCC also showed a signiﬁcantly higher proportion of homozy-
gote and non-synonymous changes (Fig. 2C and D; Supplemen-
tary Table 4). In agreement with previous studies, the number
of SNVs with a potentially damaging effect was reduced to 5 in
LGDN, 4 in HGDN, 2 in eHCC and remained highest in pHCC
(110) indicating that disruption of the transcriptome in pHCC350 Journal of Hepatology 201could be partly explained by the observed 22–55-fold increase
in deleterious genetic alterations (Supplementary Table 4)
[23,24].
A small number of SNVs in exonic regions, i.e., with high prob-
ability of functional relevance, were present in all lesions and sur-
rounding livers (UQCRHL, GLUD2, EIF5AL1, PABC3, and ERGIC3).
The only exclusive exonic and non-synonymous SNV common
for dysplastic and cancerous lesions was found in IGFALS gene
(hs16_1840768) encoding a serum protein binding the insulin-
like growth factors. The presence of this variant showed a pre-
dicted protein damaging effect (score 0.970; sensitivity: 0.77;
speciﬁcity: 0.96) and potentially led to a progressive downregu-
lation of IGFALS from HGDN to pHCC (Fig. 3A). The decrease in
IGFALS expression was conﬁrmed in >350 human HCCs4 vol. 60 j 346–353
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(Fig. 3B–F) including our previously published data set containing
eHCC (Fig. 3C) and correlated with IGFALS gene copy number loss
in human HCC (Fig. 3G) and human hepatoma cell lines (Fig. 3H)
suggesting down-regulation of IGFALS as a genetic biomarker of
hepatocarcinogenesis.Discussion
We have applied an integrative transcriptome sequencing
approach to address a central issue in human hepatocarcinogen-
esis, namely, the probability of malignant transformation of the
pre-neoplastic lesions, starting from dysplastic lesions to early
carcinoma (eHCC) and ultimately to fully progressed HCC (pHCC).
We report that genome-wide molecular analysis does not accu-
rately recapitulate the histological distinction of different lesions.
We ﬁnd that the transcriptomes of the early lesions including
eHCC were surprisingly homogenous, despite a progressive
increase in immune response and proliferation. Activation of
prognostic adverse signaling pathways in pHCC, centered on
TGFb, WNT, NOTCH, MYC, and EMT-related genes, occurred only
late during hepatocarcinogenesis. The prominent role of MYC tar-
get gene activation during the multistage malignant transforma-
tion is well recognized [25]. Although eHCC from Korean patients
with hepatitis B infection in this study did not show early c-MYC
activation, our results validate the role of c-MYC signaling in the
malignant switch to pHCC (Fig. 1C and Supplementary Fig. 4C)
[26]. Of note, the examined eHCC also lacked the expression of
other established markers (i.e., AFP, GPC3, GS, and HSP70)
(Table 1).
A unique feature of our study was a parallel analysis of the full
spectrum of early and advanced liver lesions from a single
patient. Besides a common deregulation of known pro-oncogenic
signaling such as TGFb, PI3K and WNT/b-Catenin pathways found
in the pHCC group comparison (Supplementary Fig. 4), the pHCC
in PT5 was characterized by a loss of CDKN2A as well as a dereg-
ulation of EGFR and activation of androgen receptor signaling
(Supplementary Fig. 7B–E), both implicated in gender disparity
characteristic of HCC development [27,28]. Of note, although
the same cell origin of the eHCC and pHCC from PT5 cannot be
excluded, the absence of vascular invasion and tumor metastasis
and profound differences in tumor genetics (i.e., SNVs) and tran-
scriptome are more consistent with a multicentric tumor origin
rather than intrahepatic metastasis [29]. These results under-
score the value of in-depth analyses of individual tumor samples
to identify the unique patient-speciﬁc oncogenic pathways that
are underappreciated by group comparisons. The concomitant
analyses of individual as well as common characteristics of HCCs
might open new windows for diagnostic and/or therapeutic
interventions and help to improve the individual patient survival.
The massive disruption of the transcriptome in pHCC could be
explained at least in part by a sharp rise in the spectrum of
genetic alterations (Fig. 2A). The numbers of SNVs identiﬁed in
early lesions and eHCC were consistently low but signiﬁcantly
increased upon progression to pHCC. Further, the SNVs with func-
tional consequences on gene expression, i.e., detected in genes
with differential expression in pHCC, affected key cancer-associ-
ated molecules, such as TGFb1, NOTCH2, VCAM1, JAK1, ITGA6,
ITGB1, IGF2, IGFBP5, XRCC5, DKK3, and MMP14 [30–37], suggest-
ing that genetic variations in these genes may represent acquisi-Journal of Hepatology 201tion of additional driver mutations during late stages of
hepatocarcinogenesis [38]. Notably, SNVs recently identiﬁed in
the context of hepatocarcinogenesis were exclusively present in
pHCC and associated with frequently deregulated genes such as
APC, IRF2, KRAS, MET, NFE2L1, RPS6KA1, RPS6KB2 in addition to
p53 (TP53, TP53BP2, TP53RK), WNT/b-Catenin (AXIN1), ERB (EGFR,
ERBB2, ERBB2IP) and genes involved in chromatin remodeling
(ARID3A, ARID3C, ARID4A, ARID5B) [23,24], again emphasizing
that acquisition of malignant traits is a relatively late event. We
also detected previously recognized recurrent somatic homozyg-
otic exonic SNV (rs2304347) for AZIN1 in pHCC as well as several
exonic SNVs in ADAR that might result in AZIN1 changes. These
results validate the importance of RNA editing for hepatocarcino-
genesis [39]. However, the distribution of fusion events was com-
parable within the different stages, and we did not identify any
apparent cancer driving fusion events (data not shown). Of note,
there is a possibility that some stop or frameshift mutations (e.g.,
in tumor suppressor genes), which could potentially lead to
mRNA decay, as well as mutations in non-transcribed regions
(e.g., promoter regions) could have been missed by RNA-Seq
[40]. Furthermore, no blood samples were available from the
investigated patients. Therefore, surrounding liver was used as
a reference to identify somatic mutations. Since the examined
HCCs developed in the context of HBV-induced liver cirrhosis,
we cannot exclude that some genetic/epigenetic alterations have
already occurred within the altered liver microenvironment.
Another important ﬁnding of this study was the identiﬁcation
of IGFALS as a key genetic determinant preferentially down-reg-
ulated in pHCC (Fig. 3). Notably, alterations in IGFALS were pre-
viously recognized in advanced HCC by integrating information
from different molecular layers [41]. In addition to a proposed
tumor suppressor role, we demonstrate here that the disruption
of IGFALS led to the enhanced IGF signaling [42,43] (Supplemen-
tary Fig. 8A–D) thereby providing a potential mechanism for its
role in promoting hepatocarcinogenesis. Future clinical and
translational efforts are warranted to address the potential utility
of IGFALS for routine clinical applications.
Collectively, our results have two major implications. The
homogenous expression patterns in preneoplastic lesions do
not allow to predict, which lesions progress to liver cancer, high-
lighting the importance of intensiﬁed surveillance and early
detection for successful therapeutic interventions. Secondly, the
high molecular heterogeneity of pHCC characterized by activa-
tion of the prognostic adverse pathways, such as TGFb, WNT,
NOTCH, MYC, and EMT, may underscore the poor response to
standard therapies in the current clinical trials and the need for
individualized treatment at the progressed stages of HCC. Accord-
ing to the current guidelines, lesions <1 cm are closely monitored
by ultrasound [4]. If the results of the present study are validated
in larger patient cohorts with a more diverse etiological back-
ground, they could serve as a basis for a new intensiﬁed diagnos-
tic algorithm that includes consequent biopsies of early lesions.
In particular, it can be applied to non-cirrhotic patients with a
well-preserved liver function, when early lesions are easier to
target, and biopsies can be relatively safely performed. Future
translational efforts should further evaluate if biopsies of suspi-
cious lesions during early stages of hepatocarcinogenesis could
be supported by implementation of next-generation sequence
technologies. This approach would ultimately provide a detailed
catalogue of genetic alterations during hepatocarcinogenesis that4 vol. 60 j 346–353 351
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can serve as guide for preventive treatment of the lesions (e.g.,
local ablation) and contribute to reduce HCC incidence and
recurrence.Financial support
This work was supported by the Intramural Research Program of
the NIH, National Cancer Institute, Center for Cancer Research.
This work was partly supported by the Korea Science and Engi-
neering Foundation (KOSEF) grant funded by the Korea govern-
ment (MOST) (2011-0030707) to Y.N.P. J.U.M. is supported by a
grant from the German Research Foundation (MA 4443/2-1).Conﬂict of interest
The authors who have taken part in this study declared that they
do not have anything to disclose regarding funding or conﬂict of
interest with respect to this manuscript.
Acknowledgements
This work was supported by the Intramural Research Program of
the NIH, National Cancer Institute, Center for Cancer Research.
This work was partly supported by the Korea Science and Engi-
neering Foundation (KOSEF) grant funded by the Korea govern-
ment (MOST) (2011-0030707) to Y.N.P. J.U.M. is supported by a
grant from the German Research Foundation (MA 4443/2-1).Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jhep.2013.10.
014.References
[1] Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules.
Semin Liver Dis 2005;25:133–142.
[2] Pathologic diagnosis of early hepatocellular carcinoma. A report of the
international consensus group for hepatocellular neoplasia. Hepatology
2009;49:658–664.
[3] Aihara T, Noguchi S, Sasaki Y, Nakano H, Monden M, Imaoka S. Clonal
analysis of precancerous lesion of hepatocellular carcinoma. Gastroenterol-
ogy 1996;111:455–461.
[4] European Association For The Study Of The L, European Organisation For R,
Treatment Of C. EASL-EORTC clinical practice guidelines: management of
hepatocellular carcinoma. J Hepatol 2012;56:908–943.
[5] Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al.
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl
Cancer Inst 2008;100:698–711.
[6] Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efﬁcient
alignment of short DNA sequences to the human genome. Genome Biol
2009;10:R25.
[7] Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence
alignment/map format and SAM tools. Bioinformatics 2009;25:2078–2079.
[8] Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and
quantifying mammalian transcriptomes by RNA-Seq. Nat Methods
2008;5:621–628.
[9] Wang L, Feng Z, Wang X, Wang X, Zhang X. DEGseq: an R package for
identifying differentially expressed genes from RNA-seq data. Bioinformatics
2010;26:136–138.352 Journal of Hepatology 201[10] Koboldt DC, Chen K, Wylie T, Larson DE, McLellan MD, Mardis ER, et al.
VarScan: variant detection in massively parallel sequencing of individual
and pooled samples. Bioinformatics 2009;25:2283–2285.
[11] Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic
variants from high-throughput sequencing data. Nucleic Acids Res
2010;38:e164.
[12] Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of
hepatocellular carcinoma (HCC): an emerging ﬁeld for advanced technolo-
gies. J Hepatol 2012;56:267–275.
[13] Alfano D, Votta G, Schulze A, Downward J, Caputi M, Stoppelli MP, et al.
Modulation of cellular migration and survival by c-Myc through the
downregulation of urokinase (uPA) and uPA receptor. Mol Cell Biol
2010;30:1838–1851.
[14] Alonso SR, Tracey L, Ortiz P, Perez-Gomez B, Palacios J, Pollan M, et al. A
high-throughput study in melanoma identiﬁes epithelial-mesenchymal
transition as a major determinant of metastasis. Cancer Res
2007;67:3450–3460.
[15] Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, et al. Focal
gains of VEGFA and molecular classiﬁcation of hepatocellular carcinoma.
Cancer Res 2008;68:6779–6788.
[16] Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-beta
gene expression signature in mouse hepatocytes predicts clinical outcome in
human cancer. Hepatology 2008;47:2059–2067.
[17] Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY,
et al. Integrative transcriptome analysis reveals common molecular
subclasses of human hepatocellular carcinoma. Cancer Res
2009;69:7385–7392.
[18] Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, et al. A novel
prognostic subtype of human hepatocellular carcinoma derived from
hepatic progenitor cells. NatMed 2006;12:410–416.
[19] Nguyen BC, Lefort K, Mandinova A, Antonini D, Devgan V. Della Gatta G, et al.
Cross-regulation between Notch and p63 in keratinocyte commitment to
differentiation. Genes Dev 2006;20:1028–1042.
[20] Rutella S, Bonanno G, Procoli A, Mariotti A, de Ritis DG, Curti A, et al.
Hepatocyte growth factor favors monocyte differentiation into regulatory
interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell fea-
tures. Blood 2006;108:218–227.
[21] Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, et al. PID: the
pathway interaction database. Nucleic Acids Res 2009;37:D674–D679.
[22] Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D, et al. An
integrated genomic and epigenomic approach predicts therapeutic response
to zebularine in human liver cancer. Sci Transl Med 2010;2:54ra77.
[23] Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, et al.
Integrated analysis of somatic mutations and focal copy-number changes
identiﬁes key genes and pathways in hepatocellular carcinoma. Nat Genet
2012;44:694–698.
[24] Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, et al.
Whole-genome sequencing of liver cancers identiﬁes etiological inﬂuences
on mutation patterns and recurrent mutations in chromatin regulators. Nat
Genet 2012;44:760–764.
[25] Kaposi-Novak P, Libbrecht L, Woo HG, Lee YH, Sears NC, Conner EA, et al.
Central role of c-Myc during malignant conversion in human hepatocarci-
nogenesis. Cancer Res 2009;69:2775–2782.
[26] Thorgeirsson SS. The almighty MYC: orchestrating the micro-RNA universe
to generate aggressive liver cancer. J Hepatol 2011;55:486–487.
[27] Keng VW, Sia D, Sarver AL, Tschida BR, Fan D, Alsinet C, et al. Sex bias
occurrence of hepatocellular carcinoma in Poly7 molecular subclass is
associated with EGFR. Hepatology 2013;57:120–130.
[28] Li Z, Tuteja G, Schug J, Kaestner KH. Foxa1 and Foxa2 are essential for sexual
dimorphism in liver cancer. Cell 2012;148:72–83.
[29] Roncalli M, Park YN, Di Tommaso L. Histopathological classiﬁcation of
hepatocellular carcinoma. Dig Liver Dis 2010;42:S228–S234.
[30] Chen TY, Li YC, Liu YF, Tsai CM, Hsieh YH, Lin CW, et al. Role of MMP14 gene
polymorphisms in susceptibility and pathological development to hepato-
cellular carcinoma. Ann Surg Oncol 2011;18:2348–2356.
[31] Li R, Yang Y, An Y, Zhou Y, Liu Y, Yu Q, et al. Genetic polymorphisms in DNA
double-strand break repair genes XRCC5, XRCC6 and susceptibility to
hepatocellular carcinoma. Carcinogenesis 2011;32:530–536.
[32] Luo JH, Ren B, Keryanov S, Tseng GC, Rao UN, Monga SP, et al. Transcriptomic
and genomic analysis of human hepatocellular carcinomas and hepatoblas-
tomas. Hepatology 2006;44:1012–1024.
[33] Migita K, Miyazoe S, Maeda Y, Daikoku M, Abiru S, Ueki T, et al. Cytokine
gene polymorphisms in Japanese patients with hepatitis B virus infection–
association between TGF-beta1 polymorphisms and hepatocellular carci-
noma. J Hepatol 2005;42:505–510.4 vol. 60 j 346–353
JOURNAL OF HEPATOLOGY
[34] Pei Y, Kano J, Iijima T, Morishita Y, Inadome Y, Noguchi M. Overexpression of
Dickkopf 3 in hepatoblastomas and hepatocellular carcinomas. Virchows
Arch 2009;454:639–646.
[35] Umemura A, Itoh Y, Itoh K, Yamaguchi K, Nakajima T, Higashitsuji H, et al.
Association of gankyrin protein expression with early clinical stages and
insulin-like growth factor-binding protein 5 expression in human hepato-
cellular carcinoma. Hepatology 2008;47:493–502.
[36] Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and
signaling pathways in hepatocellular carcinoma. Semin Liver Dis
2007;27:55–76.
[37] Xie HJ, Bae HJ, Noh JH, Eun JW, Kim JK, Jung KH, et al. Mutational analysis of
JAK1 gene in human hepatocellular carcinoma. Neoplasma
2009;56:136–140.
[38] Woo HG, Park ES, Lee JS, Lee YH, Ishikawa T, Kim YJ, et al. Identiﬁcation of
potential driver genes in human liver carcinoma by genomewide screening.
Cancer Res 2009;69:4059–4066.
[39] Chen L, Li Y, Lin CH, Chan TH, Chow RK, Song Y, et al. Recoding RNA editing of
AZIN1 predisposes to hepatocellular carcinoma. Nat Med 2013;19:209–216.
[40] Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, et al. High
frequency of telomerase reverse-transcriptase promoter somatic mutations
in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 2013;4.Journal of Hepatology 201[41] Neumann O, Kesselmeier M, Geffers R, Pellegrino R, Radlwimmer B,
Hoffmann K, et al. Methylome analysis and integrative proﬁling of human
HCCs identify novel protumorigenic factors. Hepatology
2012;56:1817–1827.
[42] Boudoukha S, Cuvellier S, Polesskaya A. Role of the RNA-binding protein
IMP-2 in muscle cell motility. Mol Cell Biol 2010;30:5710–5725.
[43] Kuninger D, Kuzmickas R, Peng B, Pintar JE, Rotwein P. Gene discovery by
microarray: identiﬁcation of novel genes induced during growth factor-
mediated muscle cell survival and differentiation. Genomics
2004;84:876–889.
[44] Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, et al.
Genome-wide molecular proﬁles of HCV-induced dysplasia and hepatocel-
lular carcinoma. Hepatology 2007;45:938–947.
[45] Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, et al. A unique
metastasis gene signature enables prediction of tumor relapse in early-stage
hepatocellular carcinoma patients. Cancer Res 2010;70:10202–10212.
[46] Mas VR, Maluf DG, Archer KJ, Yanek K, Kong X, Kulik L, et al. Genes involved
in viral carcinogenesis and tumor initiation in hepatitis C virus-induced
hepatocellular carcinoma. Mol Med 2009;15:85–94.4 vol. 60 j 346–353 353
